Revlimid Now Funded in Newfoundland & Labrador and New Brunswick

REVLIMID® AS FIRST-LINE TREATMENT FOR NON-TRANSPLANT ELIGIBLE MYELOMA PATIENTS NOW FUNDED IN NEWFOUNDLAND & LABRADOR AND
NEW BRUNSWICK

Myeloma Canada is pleased to announce that both Newfoundland & Labrador and

New Brunswick have agreed to fund Revlimid ® (lenalidomide) as a first-line treatment for newly-diagnosed myeloma patients who are not eligible for high-dose chemotherapy (also known as autologous stem cell transplant).

Over a year ago, Myeloma Canada made a patient submission to pCODR to advocate for access for this new indication which resulted in a positive recommendation by the committee several months later.

These are the conditions for funding in the respective

province and territory:

NEWFOUNDLAND & LABRADOR

As of December 31, 2016, Newfoundland & Labrador will begin provincially funding Revlimid. The funding criteria is as follows:

Lenalidomide as an option for first line treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment is in combination with dexamethasone for patients with an ECOG performance status of less than or equal to 2 and continued until disease progression.

This information is publicly available on their website HERE

NEW BRUNSWICK

As of December 21, 2016, New Brunswick will begin funding Revlimid. The funding criteria is as follows:

Lenalidomide as an option for first line treatment in patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG performace statuts of less than or equal to 2. Clinical Note: Treatment should be discontinued upon disease progression or unacceptable toxicity.

This information is publicly available on their website HERE

Myeloma Canada would like to thank all of the patients and caregivers who participated in the pCODR patient submission and also acknowledge both both provincial cancer agencies for their foresight of the positive benefits to patients by having this indication listed on their formularies for funding.

This is further proof that when we work together as a unified voice, we are strengthening the voice of the Canadian myeloma community. Together, we are making a difference!

Together, we are making a difference!

What's happening in social media